glp-1 rfk jr FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures RFK Jr. discusses GRAS &

In the TOGETHER-PsA trial, Merola and colleagues assessed the efficacy and safety of combination therapy with ixekizumab (Taltz, Eli Lilly) plus tirzepatide (Zepbound, Eli Lilly), compared with ixekizumab alone in a cohort of 271 adults with active PsA and overweight or obesity, aligned with the on-label dosing of both interventions

Novo Nordisk has added ileus to the Postmarketing Experience section of the Wegovy label under Gastrointestinal Disorders. In October 2025, Severe Gastrointestinal Adverse Reactions was added to the WARNING AND PRECAUTIONS section of the label

Mol Genet Metab 109:20814

Increasing Predominance of Norovirus GII.17 over GII.4, United States, 20222025